Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127605451 | 12760545 | 1 | I | 20160916 | 20160919 | 20160919 | EXP | RU-ABBVIE-16P-251-1731568-00 | ABBVIE | 0.00 | M | Y | 0.00000 | 20160919 | MD | RU | RU |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127605451 | 12760545 | 1 | PS | KALETRA | LOPINAVIRRITONAVIR | 1 | Oral | 1 TABLET (100 MG LOPINAVIR + 25 MG RITONAVIR) | U | UNKNOWN | 21906 | 2 | DF | TABLET | BID | ||||
| 127605451 | 12760545 | 2 | C | DIDANOSINE. | DIDANOSINE | 1 | Oral | 0 | 250 | MG | TABLET | QD | |||||||
| 127605451 | 12760545 | 3 | C | ABACAVIR. | ABACAVIR | 1 | Oral | 0 | 240 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127605451 | 12760545 | 1 | HIV infection |
| 127605451 | 12760545 | 2 | HIV infection |
| 127605451 | 12760545 | 3 | HIV infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127605451 | 12760545 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127605451 | 12760545 | Ascites | |
| 127605451 | 12760545 | Hepatic cirrhosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |